Tech Company Financing Transactions
Portola Pharmaceuticals Funding Round
Portola Pharmaceuticals closed a $60 million venture capital round on 7/9/2008. Backers included Adage Capital Management, BBT Fund and D. E. Shaw Group.
Transaction Overview
Company Name
Announced On
7/9/2008
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds will be used primarily to advance Portola's two lead antithrombotic clinical candidates, betrixaban and PRT060128, which the company is developing as best-in-class compounds to replace existing standards of care. In addition, funds will be used to develop the company's pre-clinical pipeline including its novel Factor Xa inhibitor antidote, which has the potential to expand the use of anticoagulants.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
270 E. Grand Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Portola Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Mard Dier
Chief Medical Officer
John Lawrence?
VP - Bus. Development
Tao Fu
VP - Engineering
Glenn Brame
VP - General Counsel
John Moriarty
VP - R & D
John Curnutte
Browse more venture capital transactions:
Prev: 7/9/2008: Xeround venture capital transaction
Next: 7/9/2008: FeedRoom venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs